#Czech Republic #Prague #Kedrion Biopharma #IPIC 2025 #Secondary Immunodeficiencies

Kedrion Biopharma Shines at IPIC 2025 with Focus on Secondary Immunodeficiencies

Kedrion Biopharma, a key player in the biopharmaceutical sector with a strong focus on plasma-derived therapies, has made a noteworthy appearance at the International Primary Immunodeficiencies Congress (IPIC) 2025, taking place from November 5 to 7 in Prague, Czech Republic. This congress serves as a premier platform for global experts to converge and discuss advancements and challenges in the realm of primary and secondary immunodeficiencies.

Highlighting Secondary Immunodeficiencies in Hematologic Malignancies

As part of the event, Kedrion hosted a dedicated Satellite Symposium titled "Secondary Immunodeficiencies in Hematologic Malignancies: A Growing Area of Interest." The symposium drew attention to the critical topic of Secondary Immunodeficiencies (SIDs), which are increasingly recognized for their complex relation to hematological conditions, particularly B-cell malignancies. With the growing prevalence of these conditions, the symposium aimed to foster greater awareness and understanding among clinicians and researchers alike.

Opening the symposium was Dr. Fabian Peissker, representing Kedrion's Medical Affairs. He emphasized the pressing need for improved diagnostic and management strategies for SIDs. The event featured insights from leading experts, including Prof. Hermann Wolf from Sigmund Freud University in Vienna and Dr. Federica Pulvirenti from Policlinico Umberto I in Rome. Their presentations addressed the multifaceted challenges clinicians face when diagnosing and treating SIDs, which pose significant risks of severe infections due to compromised immune responses.

Addressing Clinical Challenges and Patient Care

The complexities surrounding SIDs make them difficult to manage, especially in conjunction with hematologic malignancies. Patients diagnosed with conditions such as hypogammaglobulinemia and those facing recurrent infections require accurate and timely interventions. Recent developments in cancer therapies have resulted in prolonging patient life; however, these treatments often lead to complications that can jeopardize overall health and quality of life. Thus, it is imperative for healthcare practitioners to perform early diagnoses and utilize immunoglobulin replacement therapies effectively to mitigate risks.

Kedrion's commitment to tackling these issues was evident through its active participation in the symposium. As Roberto Crea, the Therapeutic Area Lead for Immunology at Kedrion, highlighted, understanding the intricate dynamics between primary and secondary immunodeficiencies is crucial. Through consistent research efforts, Kedrion aims to bridge the knowledge gap and foster collaborations among healthcare professionals to enhance patient outcomes.

Engaging the Scientific Community

Beyond the symposium, Kedrion has established a solid presence at IPIC 2025 by setting up a booth and participating in three scientific poster sessions. Each poster session is co-developed by leaders in the field and foundations dedicated to patient advocacy, presenting the latest research findings and scientific contributions. Participants visiting Kedrion's booth (#17) have the opportunity to engage directly with the company’s medical and scientific professionals, reflecting Kedrion’s approach of creating open communication channels within the healthcare community.

Collaborative Efforts in Patient Care

Collaboration is paramount in managing the complexities associated with SIDs. Martine Pergent, President of the International Patient Organization for Primary Immunodeficiencies (IPOPI), reinforced the necessity for collaborative efforts across various fields of medicine, stating that the approach towards immunodeficiencies must broaden beyond infection management. Increasing engagement with hematologists will improve comprehensive care for patients with both primary and secondary immunodeficiencies.

Conclusion: Future Directions and Community Engagement

The 2025 edition of IPIC marks a significant milestone in the ongoing dialogue surrounding primary and secondary immunodeficiencies. With over 900 participants from over 70 countries, the congress fosters a vibrant exchange of scientific knowledge and collaborative efforts to enhance patient care. Kedrion's role as a sponsor and participant illustrates its dedication to driving advancements in the treatment of immunodeficiencies. As the landscape of immunotherapy continues to evolve, Kedrion remains at the forefront, committed to improving the quality of life for patients battling these complex conditions. For further details, visit Kedrion's official page at www.kedrion.com.